A certain difference in the action mode of PKCα, such as extent and time constant of PKCα hyperactivity or collaborating factors with PKCα, might determine whether hyperactive PKCα leads to beneficial or deteriorating outcomes in the AD pathology. This evidence concerns the gene PRKCA and Alzheimer disease.